The BCR-ABL fusion oncoprotein accelerates differentiation and proliferation of myeloid cells during the chronic phase of chronic myeloid leukemia (CP-CML). Here, the role of CCAAT/enhancer binding protein b (C/EBPb), a regulator for 'emergency granulopoiesis,' in the pathogenesis of CP-CML was examined. C/EBPb expression was upregulated in Lineage
INTRODUCTION
Chronic phase chronic myeloid leukemia (CP-CML) is characterized by massive proliferation and differentiation of myeloid cells. 1, 2 In sharp contrast to acute myeloid leukemia with leukemic hiatus, both myeloid progenitors and mature granulocytes accumulate in the bone marrow, peripheral blood and spleen in CP-CML. 1 The myeloid expansion in CP-CML has been attributed to the BCR-ABL fusion protein, resulting from a translocation between chromosomes 9 and 22. [2] [3] [4] Experiments using transgenic mouse models have shown that the BCR-ABL-mediated leukemic status is reversed by suppression of BCR-ABL, [5] [6] [7] suggesting that BCR-ABL is the sole cause of the myeloid expansion in CP-CML. In practice, inhibition of the BCR-ABL tyrosine kinase activity effectively controls the disease during the chronic phase in most cases. [8] [9] [10] [11] [12] Recent findings suggested a hierarchical organization of CML hematopoiesis, with CML stem cells giving rise to heterogeneous progeny. [13] [14] [15] Accumulating clinical experiences, together with experimental data, have shown that leukemic stem cells in CP-CML are resistant to TKIs (tyrosine kinase inhibitors) and sometimes causes a relapse of the disease after discontinuation of TKI treatment. [16] [17] [18] [19] Progression of CML toward the accelerated phase and blast crisis is considered to be a consequence of further acquisition of genetic mutations, which makes the disease more resistant to TKIs and results in an extremely poor prognosis. 20, 21 Therefore, a better understanding of the characteristics of leukemic stem cells, as well as the pathogenesis of CP-CML, are essential for establishing a novel therapeutic strategy for CML.
Granulopoiesis is a process in which hematopoietic stem cells (HSCs) give rise to mature granulocytes throughout life. Our previous findings revealed that a member of the CCAAT/enhancer binding protein (C/EBP) family of transcription factors, C/EBPb, is required for 'emergency granulopoiesis,' which is characterized by the accelerated differentiation and proliferation of granulocytic precursors in response to infections or cytokine stimulation. 22 Myeloid expansion is a common feature of both emergency granulopoiesis and CP-CML. However, little is known regarding the role of C/EBPb in the pathogenesis of CP-CML. In this study, the effects of BCR-ABL on the expression and function of C/EBPb in BCR-ABL-induced myeloid expansion was determined and the therapeutic implications of these data are discussed.
MATERIALS AND METHODS

Primary human bone marrow cells and cell lines
Frozen samples of human bone marrow cells from healthy donors or untreated CP-CML patients were purchased from AllCells LLC (Emeryville, CA, USA). In all cases, written informed consent was obtained according to the Institutional Review Board or Human Subject Committee approved donor program. The characteristics of the patients are shown in Supplementary Table 1. EML cells 23 (a kind gift from Dr Schickwann Tsai at the University of Utah, UT, USA) were maintained in IMDM (Iscove modified Dulbecco's medium) supplemented with 20% heat-inactivated horse serum and 15% BHK/MKL cell-conditioned medium. Mice C57BL/6 mice were purchased from Clea Japan (Tokyo, Japan). C/EBPb knockout (KO) mice 24 were back crossed to C57BL/6 strain mice at least eight times. Whenever C/EBPb KO mice were analyzed, wild-type (WT) littermates were used as control. All mice were maintained under specific pathogen-free conditions in the Institute of Laboratory Animals, Kyoto University. All experiments were performed according to the institutional guidelines of Kyoto University.
Reagents
A STAT5 inhibitor (N 0 -((4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide) and Ly294002, a PI3K inhibitor, were purchased from Merck (Darmstadt, Germany). U0126, a MEK inhibitor, was purchased from Cell Signaling Technology (Danvers, MA, USA). Stock solutions of the STAT5 inhibitor, Ly294002, and U0126 were made in DMSO (dimethyl sulfoxide).
Plasmids
The pMSCVneo vector and pMSCV-internal ribosome entry site-green fluorescent protein (GFP) vector (MIG), 25 and their derivatives for the expression of BCR-ABL (p210), were kind gifts from Dr Keiko Okuda (Kyoto Prefectural University of Medicine, Kyoto, Japan). Retroviruses expressing the constitutively active STAT5 mutant (STAT5 1*6 ) 26 and the dominantnegative STAT5 mutant (STAT5 D749 ) 27 were kind gifts from Dr Toshio Kitamura (University of Tokyo, Tokyo, Japan).
Retrovirus infection
Plat-E packaging cells 28 were transfected with retrovirus vectors using FuGENE6 (Roche Diagnostics, Mannheim, Germany) as previously described. 22, 28 Bone marrow cells were harvested from mice (4-8 weeks of age) treated with 5-fluorouracil (5-FU) (150 mg/kg, intraperitoneally). The bone marrow cells were cultured at 37 1C for 48 h in IMDM containing 15% fetal bovine serum, 50 mM 2-mercaptoethanol, 50 ng/ml mouse stem cell factor, 50 ng/ml human thrombopoietin (a kind gift from Kyowa Hakko Kirin Co., Ltd), 50 ng/ml mouse fms-like tyrosine kinase 3 ligand (FL), and 10 ng/ml mouse interleukin-6 (IL-6). First round retroviral infection was carried out using RetroNectin (Takara Bio, Otsu, Japan) in the same medium. For the second round infection, polybrene was added with the retroviral supernatant.
Bone marrow transplantation
Recipient C57BL/6 mice (8-10 weeks of age) were lethally irradiated (10 Gy). MIG or MIG-BCR-ABL-transduced bone marrow cells (0.5-1 Â 10 5 GFP-positive cells per mouse) were injected into the tail vein of primary recipient mice. For radioprotection, 2 Â 10 5 cells of freshly harvested whole bone marrow were co-transplanted. For secondary transplantation, bone marrow cells were harvested from mice that received the primary transplants and 0.2-2 Â 10 6 GFP-positive cells were intravenously injected into sublethally irradiated secondary recipient mice. The frequencies of leukemic stem cells were calculated using the L-Calc software (StemCell Technologies, Vancouver, Canada).
Methylcellulose colony-forming assay MIG-BCR-ABL-transduced mouse bone marrow cells from C/EBPb KO or WT mice were subjected to a methylcellulose colony-forming assay using the cytokine-free medium Methocult 3231 (StemCell Technologies). The fluorescence images of the colonies were obtained using AxioCam MRm digital camera and Axio Vision software in combination with SteREO Lumar V12 microscope and Neolumar S objective lens ( Â 0.8) (Carl Zeiss, Oberkochen, Germany).
Wright Giemsa staining
Smears of mice peripheral blood or bone marrow cells and cytospin slides of EML cells or colony-forming cells were stained using a Diff-Quik kit (Sysmex, Kobe, Japan), a modified Wright Giemsa staining system. Images were obtained using DP71 digital camera and DP Controller software in combination with CX41 microscope and PlanCN objective lens ( Â 40/ 0.65 numerical aperture) (Olympus, Tokyo, Japan).
Flow cytometric analysis
Flow cytometric analysis and cell sorting were performed with a FACSCalibur, FACSCanto II, or FACSAria instrument (BD Biosciences, San Jose, CA, USA). As lineage markers for human bone marrow mononuclear cells, phycoerythrin (PE)-Cy5-conjugated anti-CD235, biotinconjugated anti-CD3, CD4, CD8, CD11b, CD14, CD19, CD20 (eBioscience, San Diego, CA, USA) and anti-CD56 antibodies (Bio Legend, San Diego, CA, USA) were used and followed by staining with streptavidin-PE-Cy5. Cells were further stained with APC (allophycocyanin)-conjugated anti-CD34 (8G12), PE-conjugated anti-CD38 (HIT2), fluorescein isothiocyanate-conjugated anti-CD45RA (HI100) (all from BD Pharmingen, San Diego, CA, USA) and PE-Cy7-conjugated anti-CD123 antibodies (eBioscience) for definition of HSCs and myeloid progenitors. For the staining of mouse cells, PerCPCy5.5-conjugated anti-CD3, CD4, CD11b, B220 and Ter119 antibodies, and PE-Cy5.5-conjugated anti-CD8 and Gr-1 antibodies (all from eBioscience) were used as lineage markers. PE-Cy7-conjugated anti-Sca-1, PE-conjugated anti-CD11b and APC-conjugated anti-c-kit antibodies (all from eBioscience) were used for definition of HSCs and myeloid cells. Data were analyzed with the FlowJo software (Tree Star, Ashland, OR, USA).
Real-time reverse transcriptase PCR Total RNA was extracted with an RNeasy Micro Kit (Qiagen, Valencia, CA, USA) and converted to cDNA using random primers. The cDNA was amplified using an Applied Biosystems Step One Plus thermal cycler (Applied Biosystems, Carlsbad, CA, USA 
Western blot analysis
Cells were diluted with equal amounts of Laemmli sample buffer and boiled at 100 1C for 10 min. Samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. A 'Can Get' Signal immunoreactions enhancer kit (Toyobo, Osaka, Japan) was used to dilute the primary and secondary antibodies. Antibodies specific for C/EBPb (sc-150, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and GAPDH (sc-25778, Santa Cruz Biotechnology) were used as primary antibodies. Immunoreactive proteins were detected using horseradish peroxidase-conjugated anti-rabbit IgG (NA934V, GE Healthcare, Little Chalfont, UK) and visualized using enhanced chemiluminescence (GE Healthcare).
Statistics
Statistical analyses were performed using Student's t-test. Survival of mice was analyzed using the log-rank test. P-values o0.05 were considered statistically significant.
RESULTS
C/EBPb is upregulated in bone marrow HSCs and myeloid progenitors from patients with CP-CML C/EBPb expression is upregulated or maintained in normal myeloid progenitors during emergency granulopoiesis, while the expression of all other C/EBP family members was downregulated. 22 Therefore, the expression of C/EBPb in bone marrow cells of patients with CP-CML was examined. Among the lineage marker negative (Lin À ) bone marrow cells, the frequency of CD34 þ CD38 À HSCs was lower and the frequency of CD34 þ CD38 þ myeloid progenitors was higher in CP-CML bone marrow than in bone marrow from healthy donors (Figures 1a and b ; Supplementary Figure S1 ). The CD34 þ CD38 þ population was further subdivided into common myeloid progenitors (CMPs), granulocyte-macrophage progenitors (GMPs) and megakaryocyte-erythrocyte progenitors (MEPs) based on the expression levels of CD123 and CD45RA 29 ( Figure 1a ). The frequency of GMPs was significantly lower and that of MEPs was significantly higher (approximately twofold) in CP-CML bone marrow than in bone marrow from healthy donors (Figure 1c ).
The differences between normal and CP-CML bone marrow in the frequency of CD34 þ CD38 À HSCs and of myeloid progenitors were consistent with previous findings. 13, 15, 30 The expression of C/EBPb in the purified progenitors was measured. The levels of C/EBPb mRNA in HSCs and all the myeloid progenitors from CP-CML bone marrow were significantly higher than the levels in bone marrow from healthy donors (Figure 1d , healthy donors, n ¼ 6; CP-CML, n ¼ 5; GMPs, Po0.01; HSCs, CMPs and MEPs, Po0.05). These results suggest that C/EBPb is upregulated in HSCs and myeloid progenitors in patients with CP-CML.
BCR-ABL upregulates C/EBPb in EML cells, a mouse HSC line
The presence of the BCR-ABL fusion protein is thought to be the only difference between normal hematopoiesis and BCR-ABLmediated myeloid expansion in CP-CML. 2, 4 To assess whether BCR-ABL could upregulate C/EBPb, the BCR-ABL gene was retrovirally introduced into a factor-dependent mouse HSC line, EML cells, and the expression of C/EBPb was compared with EML cells transduced with a control vector (EML-control). After transduction with BCR-ABL, EML cells (EML-BCR-ABL) became factor-independent and could be cultured long term in the absence of stem cell factor-containing conditioned medium.
The morphologies of the EML-control and EML-BCR-ABL cells were indistinguishable by Giemsa staining (Figure 2a , day 0). The parent EML cells expressed c-kit but not CD11b. Flow cytometric analysis of the transduced cells revealed that a small subset of EML-BCR-ABL expressed c-kit at a slightly lower intensity and expressed CD11b weakly ( Figure 2b , day 0). Myeloid differentiation of EML cells can be induced by the addition of IL-3, retinoic acid and GM-CSF (granulocyte-macrophage colony stimulating factor). 23 As shown in Figure 2a (day 5), myeloid differentiation of both EML-control and EML-BCR-ABL cells was effectively induced. Lower c-kit and higher CD11b expression by EML-control cells was observed 5 days after the induction of differentiation and the extent of the changes in the expression of c-kit and CD11b was more evident in EML-BCR-ABL cells (Figure 2b ). These results suggest that BCR-ABL enhanced myeloid differentiation of immature cells such as EML cells.
The amount of C/EBPb mRNA in undifferentiated EML-BCR-ABL cells was 1.87-fold higher than in undifferentiated EML-control cells (Figure 2c ). When the c-kit þ CD11b À fraction of the EMLcontrol cells and EML-BCR-ABL cells was analyzed, a significant difference was still observed 2.26-fold higher in EML-BCR-ABL cells (Figure 2d) , suggesting that the upregulation of C/EBPb was Ly294002, C/EBPb expression was not affected (Figure 3a) . In contrast, treatment with the STAT5 inhibitor (N 0 -((4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide) significantly reduced C/EBPb expression in EML-BCR-ABL cells (Figure 3b) . A dominantnegative STAT5 mutant, STAT5 D749 , was introduced into the EMLderived cell lines to inhibit STAT5. STAT5
D749 significantly repressed the expression of C/EBPb in EML-BCR-ABL cells but had no effect in EML-control cells (Figure 3c) . Conversely, when a constitutively active STAT5 mutant, STAT5 1*6 , was retrovirally transduced into the parental EML cells (EML-CA-STAT5), C/EBPb mRNA levels were significantly greater compared with the level in EML cells transduced with a control vector (Figure 3d ). These results suggest that STAT5 is involved in the BCR-ABL-mediated upregulation of C/EBPb.
C/EBPb regulates BCR-ABL-mediated proliferation and differentiation of myeloid cells in vitro
The upregulation of C/EBPb in the presence of BCR-ABL was confirmed using primary bone marrow cells. BCR-ABL was retrovirally introduced into bone marrow cells obtained from 5-FU-treated WT mice and RNA was extracted from purified c-kit To understand the role of C/EBPb in BCR-ABL-mediated myeloid expansion, BCR-ABL and GFP were retrovirally introduced into bone marrow cells obtained from 5-FU-treated C/EBPb KO mice and their properties were compared with BCR-ABLtransduced bone marrow cells from WT mice. The transduced cells were first subjected to cytokine-free semisolid methylcellulose culture. All the colonies formed on day 7 were GFP-positive and the numbers of colonies were equivalent between transduced bone marrow cells from WT and KO mice (Figures 4b and c) , suggesting that the frequencies of clonogenic progenitors were similar. The majority of C/EBPb KO cell-derived colonies were smaller in size (Figure 4b ) and the cell number per C/EBPb KO cell colony was significantly lower than WT cell colonies (Po0.01) (Figure 4d ). These findings suggest that the loss of C/EBPb impaired BCR-ABL-mediated cell proliferation. Having observed a difference between WT and C/EBPb KO cells in proliferative capacity in the presence of the BCR-ABL fusion protein, the morphologies of the colony-forming cells were assessed by Giemsa staining (Figure 4e) . The BCR-ABL-transduced C/EBPb KO cell colonies contained more immature myeloid cells with larger nuclei and basophilic cytoplasm, whereas the BCR-ABL-transduced WT cell colonies contained more mature neutrophilic granulocytes and macrophages (Figure 4e ). Flow cytometric analysis revealed that the BCR-ABL-transduced C/EBPb KO cells gave rise to a significantly higher proportion of c-kit þ cells and a lower proportion of CD11b þ cells, relative to BCR-ABL-transduced WT cells (%c-kit þ cells ¼ 6.7 ± 1.0% vs 2.0 ± 0.2%, P ¼ 0.01; % CD11b þ cells ¼ 17.9 ± 4.4% vs 41.3 ± 8.8%, P ¼ 0.039) (Figures 4f  and g ). In addition, BCR-ABL-transduced C/EBPb KO cells-derived colonies could be replated more than three times in cytokine-free medium, whereas BCR-ABL-transduced WT cells stopped growing after being replated only twice (Figure 4h ; Supplementary Figure S2 ). These results suggest that the C/EBPb deficiency abolished the BCR-ABL-mediated proliferation and differentiation of myeloid cells.
Loss of C/EBPb delays BCR-ABL-mediated myeloid expansion in vivo BCR-ABL-transduced bone marrow cells from C/EBPb KO mice or WT mice were transplanted into lethally irradiated recipient mice to clarify the role of C/EBPb in the in vivo myeloproliferation induced by BCR-ABL. After transplantation of transduced cells, increases in neutrophilic granulocytes were observed in the peripheral blood of mice having received either WT cells or KO cells (Figure 5a ). Flow cytometric analysis of peripheral blood also revealed that over 70% of nucleated cells were CD11b þ in both WT and KO transplant recipients (Figure 5b) . In mice transplanted with BCR-ABL-transduced C/EBPb KO cells, the increase in white blood cell count (Figure 5c ) and the development of splenomegaly ( Figure 5d (Figures 6a and b) .
Serial transplantation experiments were carried out to determine the role of C/EBPb in the loss of self-renewal capacity. When 2 Â 10 6 GFP þ bone marrow cells from the primary recipients were transplanted into sublethally irradiated secondary recipients, all the mice having received either BCR-ABL-transduced WT cells or BCR-ABL-transduced KO cells developed a myeloproliferative status, reminiscent of the first transplantation (Figure 6c ). After transplantation of 1 Â 10 6 GFP þ bone marrow cells from the primary transplant recipients, one of the four recipient mice that received a secondary transplant of BCR-ABL-transduced WT cells developed a myeloproliferative status and four out of five recipient mice that received a secondary transplant of BCR-ABLtransduced C/EBPb KO cells developed a myeloproliferative disorder (Figure 6d ). On day 38 after the secondary transplantation of 1 Â 10 6 GFP þ bone marrow cells, BCR-ABL-transduced C/EBPb KO cells achieved a significantly higher degree of chimerism in the peripheral blood of the secondary recipients than BCR-ABL-transduced WT cells (n ¼ 8 each, P ¼ 0.013) (Figure 6e) . None of the mice that received o0.5 Â 10 6 GFP þ bone marrow cells from the primary recipients developed a myeloproliferative status. Based on these transplantation experiments, the estimated frequencies of leukemia-initiating cells in bone marrow of primary recipient mice transplanted with BCR-ABL-transduced WT cells and BCR-ABL-transduced C/EBPb KO cells were 1 in 1 404 129 and 1 in 683 773, respectively (Figure 6f ). These results suggest that enhanced C/EBPb expression induced by BCR-ABL was involved in the loss of the selfrenewal potential of leukemic stem cells.
DISCUSSION
Proliferation and differentiation of myeloid cells are unique to CP-CML. This is the first report demonstrating that the BCR-ABLmediated myeloid expansion in CP-CML is promoted by C/EBPb, a regulator of 'emergency granulopoiesis.' One of the major findings of this study is the upregulation of C/ EBPb by BCR-ABL in CP-CML. In EML cells or in immature mouse hematopoietic cells, BCR-ABL upregulated C/EBPb and accelerated the differentiation of these cells (Figures 2b-e and  Figure 4a ). In contrast, previous reports showed that, in 32Dcl3 cells transduced with BCR-ABL, C/EBPb was downregulated and granulocytic differentiation was blocked. 37, 38 One explanation for the discrepancy between the observations in EML cells and 32Dcl3 cells may be due to the differentiation status. 32Dcl3 cells give rise only to neutrophilic granulocytes in the presence of G-CSF, 39 while EML cells are multipotent and can give rise to monocytic, erythroid and lymphoid lineages, in addition to the granulocytic lineage, 23 suggesting that EML cells represent more immature hematopoietic cells than 32Dcl3 cells. The higher C/EBPb Figure S3 ) also supports this idea, as C/EBPb is upregulated during myeloid differentiation. 40, 41 Taking into account the previous findings that HSCs are the target cell population for BCR-ABL during chronic phase, 4 the data from EML cells are most likely to reflect conditions of CP-CML. Consistent with our observations, Minami et al. 42 found that C/EBPb is one of the markedly upregulated genes in a pluripotent hematopoietic cell line transduced with BCR-ABL. Most importantly, C/EBPb is upregulated in purified HSCs and myeloid progenitors obtained from patients with CP-CML, as shown in Figure 1d . The differences in BCR-ABL-mediated regulation of C/EBPb in EML cells and in 32Dcl3 cells also suggested the involvement of cell context-dependent machinery. Guerzoni et al. 37 described a downregulation of C/EBPb associated with the progression of CML toward a blast crisis, whereas our study focused on the upregulation of C/EBPb in the chronic phase. The changes in the BCR-ABL-mediated regulation of C/EBPb during the progression of CML may be a consequence of genetic or epigenetic changes, which result in a cell context similar to 32Dcl3 cells, in terms of the regulation of C/EBPb.
BCR-ABL activates a number of signaling cascades through its tyrosine kinase activity. STAT5 is a well-known target of BCR-ABL. STAT5 is phosphorylated by JAK2 (ref. 43) and is thought to activate target genes to induce or maintain CP-CML. 33, 44 Our current data strongly suggest that C/EBPb resides downstream of STAT5. Transplantation of BCR-ABL-transduced STAT5 KO bone marrow cells resulted in delayed progression of a myeloproliferative disorder in mice, 33 a phenotype highly similar to our CP-CML model using C/EBPb KO cells. The similarities between the behavior of BCR-ABL-transduced STAT5 KO cells and BCR-ABLtransduced C/EBPb KO cells strongly suggested that these two molecules act sequentially in the same pathway. STAT5 and C/EBPb are both essential for cytokine-induced granulopoiesis, 22, [45] [46] [47] suggesting that STAT5 and C/EBPb may also interact when emergency granulopoiesis is stimulated. There has been no evidence, thus far, to demonstrate that STAT5 directly regulates C/EBPb. The consensus binding site for STAT5 (TTCN 3 GAA) is not found in the proximal promoter region of C/EBPb. Recently, Zhang et al. 48 showed that STAT3 regulates C/EBPb transcription through binding to the IL-6 response element II (CTGGGA) located at À 1180 base pairs in the C/EBPb promoter. However, our preliminary analysis of the 2000 base pairs proximal promoter region of C/EBPb by reporter assay failed to identify the positive regulatory elements which respond to STAT5 (data not shown). In addition, specific binding of STAT5 to the particular regulatory element was not observed in published chromatin immunoprecipitation sequencing data analyzing T cells stimulated with IL-2 (GSE12346 (ref. 49) and GSE26553 (ref. 50) ). These Our present data showed that myeloid expansion was delayed when BCR-ABL was transduced into C/EBPb KO bone marrow cells, clearly suggesting the involvement of C/EBPb in the enhanced myelopoiesis observed in patients with CP-CML. The effects of BCR-ABL on the self-renewing potential of HSCs are still controversial. Schemionek et al. 51 recently reported that BCR-ABL partially impaired long-term HSCs. In the present study, a phenotypically and functionally immature status was maintained in a greater fraction of BCR-ABL-transduced C/EBPb KO cells than in BCR-ABL-transduced WT cells both in vitro and in vivo. These data suggested that C/EBPb is involved in the BCR-ABL-mediated loss of self-renewing potential of the HSCs. From the therapeutic point of view, repression of C/EBPb in CP-CML patients would delay the progression of the disease, although leaving leukemic stem cells relatively intact. This strategy might be effective for patients with BCR-ABL mutations that are resistant to TKIs, as the role of C/EBPb in the pathogenesis of CP-CML should be common to all BCR-ABL mutants. Alternatively, upregulation of C/EBPb in leukemic stem cells might induce exhaustion of the leukemic stem cells, leading to a complete cure for the disease. Actually, Guerzoni et al. 37, 52 showed that transduction of C/EBPb promotes differentiation of BCR-ABL-expressing cells. The effects of upregulation of endogenous C/EBPb on leukemic stem cells should be determined in the future. Further understanding of the regulation of the self-renewal and differentiation of leukemic stem cells in CP-CML may lead to identification of novel therapies for CML based on the regulation of C/EBPb.
The leukocytosis observed during infections ( ¼ emergency granulopoiesis) is sometimes called a 'leukemoid' reaction because of the great increase in the number of myeloid cells with a 'left shift' in the shape of the nucleus. 53 Here, a molecular link between leukemoid reactions and CP-CML was identified. C/EBPb fine tunes the proliferation and differentiation of HSCs and CML leukemic stem cells in response to their respective upstream signals. Further elucidation of the molecular mechanisms that regulate the self-renewal and differentiation of stem cells in CP-CML and emergency granulopoiesis will facilitate the development of novel strategies for the treatment of CML. 
